Fortrea (NASDAQ:FTRE) and Bionano Genomics (NASDAQ:BNGO) Head to Head Review

Fortrea (NASDAQ:FTRE) and Bionano Genomics (NASDAQ:BNGO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Volatility and Risk

Fortrea has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Institutional & Insider Ownership

11.3% of Bionano Genomics shares are owned by institutional investors. 0.7% of Fortrea shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Fortrea and Bionano Genomics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	2	4	6	1	2.46
Bionano Genomics	1	0	1	0	2.00

Fortrea presently has a consensus price target of $23.95, indicating a potential upside of 17.08%. Bionano Genomics has a consensus price target of $6.00, indicating a potential upside of 445.45%. Given Bionano Genomics’ higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Fortrea.

Profitability

This table compares Fortrea and Bionano Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortrea	-2.58%	13.98%	2.76%
Bionano Genomics	-106.58%	-78.78%	-48.54%

Earnings & Valuation

This table compares Fortrea and Bionano Genomics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72 billion	0.72	-$986.20 million	($0.73)	-28.03
Bionano Genomics	$28.51 million	0.54	-$26.40 million	($3.02)	-0.36

Bionano Genomics has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Summary

Fortrea beats Bionano Genomics on 11 of the 15 factors compared between the two stocks.

About Fortrea

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

About Bionano Genomics

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.